Search for a trial

Top Institute Pharma (TIP) - research UMCU-rheumatology:
*Metabolic adverse events/co-morbidity in chronic rheumatoid arthritis patients*

- To systematically determine the influence of disease activity of RA on the metabolic syndrome of patients with chronic RA (disease duration > 2 years).

A multicenter, randomized, double-blind, placebo-controlled, crossover trial to evaluate the effects of evolocumab added to standard lipid-lowering therapy on fasting and post fat load lipids in patients with Familial Dysbetalipoproteinemia.

To evaluate the effect of 12 weeks subcutaneous evolocumab (140 mg pre-filled pen every 2 weeks) compared to placebo on post fat load non-HDL-C levels in 30 subjects with FD, in a multicenter, randomized, placebo-controlled, double-blind, crossover…